Skip to content

Biohaven BHVN Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

uniQure logo
uniQureQURE
$242K-93.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$169K-2,917%
Roivant Sciences logo
Roivant SciencesROIV
Biogen logo
BiogenBIIB
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's other noncash income (expense)?
Biohaven (BHVN) reported other noncash income (expense) of $837K in Q1 2026.
How has Biohaven's other noncash income (expense) changed year-over-year?
Biohaven's other noncash income (expense) decreased by 70.6% year-over-year, from $2.84M to $837K.
What is the long-term trend for Biohaven's other noncash income (expense)?
Over 3 years (2022 to 2025), Biohaven's other noncash income (expense) has grown at a -37.9% compound annual growth rate (CAGR), from -$726K to -$174K.
What does other noncash income (expense) mean?
This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.